OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Medical Virology is 65. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Omicron variant of SARS‐CoV‐2: Genomics, transmissibility, and responses to current COVID‐19 vaccines	622
Omicron and Delta variant of SARS‐CoV‐2: A comparative computational study of spike protein	414
Post‐acute COVID‐19 syndrome (PCS) and health‐related quality of life (HRQoL)—A systematic review and meta‐analysis	385
The emergence and epidemic characteristics of the highly mutated SARS‐CoV‐2 Omicron variant	355
Vaccine hesitancy: Beliefs and barriers associated with COVID‐19 vaccination among Egyptian medical students	303
Role of Toll‐like receptors in the pathogenesis of COVID‐19	274
Characterization of the novel SARS‐CoV‐2 Omicron (B.1.1.529) variant of concern and its global perspective	224
Current evidence on efficacy of COVID‐19 booster dose vaccination against the Omicron variant: A systematic review	218
OMICRON (B.1.1.529): A new SARS‐CoV‐2 variant of concern mounting worldwide fear	205
A brief review of influenza virus infection	204
Epidemiological trends and clinical features of the ongoing monkeypox epidemic: A preliminary pooled data analysis and literature review	185
Sequence analysis of the emerging SARS‐CoV‐2 variant Omicron in South Africa	182
Chronic COVID syndrome: Need for an appropriate medical terminology for long‐COVID and COVID long‐haulers	169
A large‐scale meta‐analytic atlas of mental health problems prevalence during the COVID‐19 early pandemic	168
SARS‐CoV‐2 ORF9b antagonizes type I and III interferons by targeting multiple components of the RIG‐I/MDA‐5–MAVS, TLR3–TRIF, and cGAS–STING signaling pathways	167
Relative instantaneous reproduction number of Omicron SARS‐CoV‐2 variant with respect to the Delta variant in Denmark	165
Omicron variant (B.1.1.529) of SARS‐CoV‐2, a global urgent public health alert!	153
Omicron variant genome evolution and phylogenetics	153
Droplet digital PCR of viral ‎DNA/RNA, current progress, challenges, and future perspectives	133
Omicron (BA.1) and sub‐variants (BA.1.1, BA.2, and BA.3) of SARS‐CoV‐2 spike infectivity and pathogenicity: A comparative sequence and structural‐based computational assessment	130
Preliminary report on severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Spike mutation T478K	129
Long COVID syndrome‐associated brain fog	126
Emergence of Omicron third lineage BA.3 and its importance	123
Autoimmune complications of COVID‐19	113
Safety of COVID‐19 vaccines	112

Obesity aggravates COVID‐19: An updated systematic review and meta‐analysis	111
Risk factors prediction, clinical outcomes, and mortality in COVID‐19 patients	103
Role of toll‐like receptors in modulation of cytokine storm signaling in SARS‐CoV‐2‐induced COVID‐19	102
Where have all the viruses gone? Disappearance of seasonal respiratory viruses during the COVID‐19 pandemic	102
Non‐life‐threatening adverse effects with COVID‐19 mRNA‐1273 vaccine: A randomized, cross‐sectional study on healthcare workers with detailed self‐reported symptoms	102
Anemia is associated with severe illness in COVID‐19: A retrospective cohort study	97
Evolutionary dynamics of SARS‐CoV‐2 nucleocapsid protein and its consequences	96
Genomic annotation and molecular evolution of monkeypox virus outbreak in 2022	95
Characterization of the significant decline in humoral immune response six months post‐SARS‐CoV‐2 mRNA vaccination: A systematic review	95
Defining IL‐6 levels in healthy individuals: A meta‐analysis	94
SARS‐CoV‐2 variants and vulnerability at the global level	91
Re‐emerging human monkeypox: A major public‐health debacle	90
Post‐COVID syndrome: A single‐center questionnaire study on 1007 participants recovered from COVID‐19	90
COVID‐19 vaccinations: The unknowns, challenges, and hopes	90
The inflammatory markers of multisystem inflammatory syndrome in children (MIS‐C) and adolescents associated with COVID‐19: A meta‐analysis	90
Evaluation of seven commercial RT‐PCR kits for COVID‐19 testing in pooled clinical specimens	89
The global impact of COVID‐19 pandemic on the incidence of pediatric new‐onset type 1 diabetes and ketoacidosis: A systematic review and meta‐analysis	88
Correlation between a quantitative anti‐SARS‐CoV‐2 IgG ELISA and neutralization activity	88
The outbreak of SARS‐CoV‐2 Omicron lineages, immune escape, and vaccine effectivity	88
The global epidemic of SARS‐CoV‐2 variants and their mutational immune escape	83
Cycle threshold values in RT‐PCR to determine dynamics of SARS‐CoV‐2 viral load: An approach to reduce the isolation period for COVID‐19 patients	82
Effects of SARS‐CoV‐2 mutations on protein structures and intraviral protein–protein interactions	81
COVID‐19 vaccines mix‐and‐match: The concept, the efficacy and the doubts	80
Epidemiologic characteristics of cases with reinfection, recurrence, and hospital readmission due to COVID‐19: A systematic review and meta‐analysis	79
Impact of COVID‐19 in patients with concurrent co‐infections: A systematic review and meta‐analyses	76
SARS‐CoV‐2 B.1.617 Indian variants: Are electrostatic potential changes responsible for a higher transmission rate?	76
Kidney involvement in COVID‐19 and its treatments	73
Herpes zoster emergence following mRNA COVID‐19 vaccine	72
Vitamin D deficiency is associated with COVID‐19 positivity and severity of the disease	72
Coronapp: A web application to annotate and monitor SARS‐CoV‐2 mutations	71
Clinical study evaluating the efficacy of ivermectin in COVID‐19 treatment: A randomized controlled study	71
In silico analyses on the comparative sensing of SARS‐CoV‐2 mRNA by the intracellular TLRs of humans	71
Post‐COVID syndrome symptoms, functional disability, and clinical severity phenotypes in hospitalized and nonhospitalized individuals: A cross‐sectional evaluation from a community COVID rehabilitatio	70
Differences in incidence and fatality of COVID‐19 by SARS‐CoV‐2 Omicron variant versus Delta variant in relation to vaccine coverage: A world‐wide review	69
Omicron (B.1.1.529) variant of SARS‐CoV‐2: Concerns, challenges, and recent updates	68
Molecular evolutionary characteristics of SARS‐CoV‐2 emerging in the United States	68
Placental SARS‐CoV‐2 in a pregnant woman with mild COVID‐19 disease	68
Monkeypox: A potential global threat?	67
Proportion of asymptomatic infection and nonsevere disease caused by SARS‐CoV‐2 Omicron variant: A systematic review and analysis	67
Characteristics of the first 1119 SARS‐CoV‐2 Omicron variant cases, in Marseille, France, November−December 2021	65